TW201714605A - 具有可逆的連續及分散相之奈米乳液 - Google Patents
具有可逆的連續及分散相之奈米乳液 Download PDFInfo
- Publication number
- TW201714605A TW201714605A TW105134148A TW105134148A TW201714605A TW 201714605 A TW201714605 A TW 201714605A TW 105134148 A TW105134148 A TW 105134148A TW 105134148 A TW105134148 A TW 105134148A TW 201714605 A TW201714605 A TW 201714605A
- Authority
- TW
- Taiwan
- Prior art keywords
- oil
- weight
- nanoemulsion
- phase
- water
- Prior art date
Links
- 239000007908 nanoemulsion Substances 0.000 title claims abstract description 317
- 230000002441 reversible effect Effects 0.000 title abstract description 6
- 239000012071 phase Substances 0.000 claims abstract description 173
- 239000008346 aqueous phase Substances 0.000 claims abstract description 150
- 238000000034 method Methods 0.000 claims abstract description 114
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 63
- 239000004094 surface-active agent Substances 0.000 claims abstract description 25
- 239000002562 thickening agent Substances 0.000 claims abstract description 25
- 239000002086 nanomaterial Substances 0.000 claims abstract description 24
- 239000003381 stabilizer Substances 0.000 claims abstract description 24
- 239000003921 oil Substances 0.000 claims description 222
- 235000019198 oils Nutrition 0.000 claims description 221
- -1 barium oleate Ester Chemical class 0.000 claims description 53
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 43
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 36
- 239000000194 fatty acid Substances 0.000 claims description 36
- 229930195729 fatty acid Natural products 0.000 claims description 36
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 29
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 25
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 24
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 23
- 239000003240 coconut oil Substances 0.000 claims description 22
- 235000019864 coconut oil Nutrition 0.000 claims description 22
- 239000004359 castor oil Substances 0.000 claims description 21
- 235000019438 castor oil Nutrition 0.000 claims description 21
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- 235000021355 Stearic acid Nutrition 0.000 claims description 19
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 19
- 239000008117 stearic acid Substances 0.000 claims description 19
- 239000004202 carbamide Substances 0.000 claims description 17
- 229920000136 polysorbate Polymers 0.000 claims description 15
- 239000005662 Paraffin oil Substances 0.000 claims description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 14
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 229920001223 polyethylene glycol Polymers 0.000 claims description 14
- 239000010642 eucalyptus oil Substances 0.000 claims description 13
- 229940044949 eucalyptus oil Drugs 0.000 claims description 13
- 235000019482 Palm oil Nutrition 0.000 claims description 12
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 12
- 239000008169 grapeseed oil Substances 0.000 claims description 12
- 239000002540 palm oil Substances 0.000 claims description 12
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 11
- 235000011187 glycerol Nutrition 0.000 claims description 11
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 11
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 11
- 239000002105 nanoparticle Substances 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 claims description 9
- 229940086555 cyclomethicone Drugs 0.000 claims description 9
- 150000004665 fatty acids Chemical class 0.000 claims description 9
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- 239000000811 xylitol Substances 0.000 claims description 8
- 235000010447 xylitol Nutrition 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- 229960002675 xylitol Drugs 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 7
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 7
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 7
- 235000019197 fats Nutrition 0.000 claims description 7
- 229940041616 menthol Drugs 0.000 claims description 7
- 229940031439 squalene Drugs 0.000 claims description 7
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims description 7
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000341 volatile oil Substances 0.000 claims description 7
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 claims description 6
- 239000005639 Lauric acid Substances 0.000 claims description 6
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 6
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 6
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N palmityl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 claims description 6
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 claims description 6
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- 239000010677 tea tree oil Substances 0.000 claims description 6
- 229940111630 tea tree oil Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 239000004386 Erythritol Substances 0.000 claims description 5
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 5
- 235000019414 erythritol Nutrition 0.000 claims description 5
- 229940009714 erythritol Drugs 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- IGFHQQFPSIBGKE-UHFFFAOYSA-N Nonylphenol Natural products CCCCCCCCCC1=CC=C(O)C=C1 IGFHQQFPSIBGKE-UHFFFAOYSA-N 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 4
- 235000021323 fish oil Nutrition 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 229960002442 glucosamine Drugs 0.000 claims description 4
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 claims description 4
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical compound CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 239000010668 rosemary oil Substances 0.000 claims description 4
- 229940058206 rosemary oil Drugs 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 3
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 claims description 3
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 3
- FCTMFTCHMVUGTA-UHFFFAOYSA-N 2,3,4,4a-tetrahydrocyclopenta[b]pyran Chemical compound O1C=2C(CCC1)C=CC=2 FCTMFTCHMVUGTA-UHFFFAOYSA-N 0.000 claims description 3
- HNUQMTZUNUBOLQ-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO HNUQMTZUNUBOLQ-UHFFFAOYSA-N 0.000 claims description 3
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 3
- JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 claims description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 claims description 3
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 claims description 3
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 235000019500 Grapefruit seed oil Nutrition 0.000 claims description 3
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 3
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 108010038807 Oligopeptides Proteins 0.000 claims description 3
- 102000015636 Oligopeptides Human genes 0.000 claims description 3
- 239000008118 PEG 6000 Substances 0.000 claims description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 3
- 229920002367 Polyisobutene Polymers 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- WPMWEFXCIYCJSA-UHFFFAOYSA-N Tetraethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCO WPMWEFXCIYCJSA-UHFFFAOYSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 claims description 3
- 229940072107 ascorbate Drugs 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000021302 avocado oil Nutrition 0.000 claims description 3
- 239000008163 avocado oil Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229960004203 carnitine Drugs 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 3
- 229940113120 dipropylene glycol Drugs 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 235000008524 evening primrose extract Nutrition 0.000 claims description 3
- 239000010475 evening primrose oil Substances 0.000 claims description 3
- 229940089020 evening primrose oil Drugs 0.000 claims description 3
- 125000005456 glyceride group Chemical group 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- 150000002337 glycosamines Chemical class 0.000 claims description 3
- 229940031575 hydroxyethyl urea Drugs 0.000 claims description 3
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 229960000367 inositol Drugs 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 3
- 229940060384 isostearyl isostearate Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 235000008390 olive oil Nutrition 0.000 claims description 3
- 239000004006 olive oil Substances 0.000 claims description 3
- 229920001992 poloxamer 407 Polymers 0.000 claims description 3
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229960004063 propylene glycol Drugs 0.000 claims description 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical group 0.000 claims description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- PHMNXPYGVPEQSJ-UHFFFAOYSA-N Dimethoxane Chemical compound CC1CC(OC(C)=O)OC(C)O1 PHMNXPYGVPEQSJ-UHFFFAOYSA-N 0.000 claims description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 claims description 2
- 239000012502 diagnostic product Substances 0.000 claims description 2
- 239000003845 household chemical Substances 0.000 claims description 2
- 239000010690 paraffinic oil Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 229940127557 pharmaceutical product Drugs 0.000 claims description 2
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 2
- 239000000845 maltitol Substances 0.000 claims 2
- 235000010449 maltitol Nutrition 0.000 claims 2
- 229940035436 maltitol Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 235000010446 mineral oil Nutrition 0.000 claims 2
- 229940057874 phenyl trimethicone Drugs 0.000 claims 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 claims 2
- WWVBRUMYFUDEJQ-UHFFFAOYSA-N 1-ethoxyethane-1,2-diol Chemical compound CCOC(O)CO WWVBRUMYFUDEJQ-UHFFFAOYSA-N 0.000 claims 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims 1
- VKYBUEJAQKBUFU-UHFFFAOYSA-N hexylhydrazine Chemical compound CCCCCCNN VKYBUEJAQKBUFU-UHFFFAOYSA-N 0.000 claims 1
- 229920000223 polyglycerol Polymers 0.000 claims 1
- 230000008719 thickening Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 description 77
- 230000000845 anti-microbial effect Effects 0.000 description 66
- 238000012360 testing method Methods 0.000 description 65
- 238000003756 stirring Methods 0.000 description 30
- 230000000694 effects Effects 0.000 description 27
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 24
- 239000001587 sorbitan monostearate Substances 0.000 description 23
- 235000011076 sorbitan monostearate Nutrition 0.000 description 23
- 229940035048 sorbitan monostearate Drugs 0.000 description 23
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 20
- 239000008213 purified water Substances 0.000 description 18
- 235000013871 bee wax Nutrition 0.000 description 12
- 239000012166 beeswax Substances 0.000 description 12
- 229930003427 Vitamin E Natural products 0.000 description 11
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 11
- 235000019165 vitamin E Nutrition 0.000 description 11
- 229940046009 vitamin E Drugs 0.000 description 11
- 239000011709 vitamin E Substances 0.000 description 11
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 10
- 235000017471 coenzyme Q10 Nutrition 0.000 description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 7
- 238000013019 agitation Methods 0.000 description 7
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000237502 Ostreidae Species 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 235000020636 oyster Nutrition 0.000 description 4
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 235000012754 curcumin Nutrition 0.000 description 3
- 239000004148 curcumin Substances 0.000 description 3
- 229940109262 curcumin Drugs 0.000 description 3
- 229960001259 diclofenac Drugs 0.000 description 3
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 3
- 229960001596 famotidine Drugs 0.000 description 3
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 3
- 229960000201 isosorbide dinitrate Drugs 0.000 description 3
- 229960004125 ketoconazole Drugs 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 3
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 3
- 229960002722 terbinafine Drugs 0.000 description 3
- 239000007762 w/o emulsion Substances 0.000 description 3
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 244000208874 Althaea officinalis Species 0.000 description 2
- 235000006576 Althaea officinalis Nutrition 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960002206 bifonazole Drugs 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 235000012680 lutein Nutrition 0.000 description 2
- 239000001656 lutein Substances 0.000 description 2
- 229960005375 lutein Drugs 0.000 description 2
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 2
- 235000001035 marshmallow Nutrition 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VLDFMKOUUQYFGF-UHFFFAOYSA-N 4-(butoxymethyl)-2-methoxyphenol Chemical compound CCCCOCC1=CC=C(O)C(OC)=C1 VLDFMKOUUQYFGF-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000010632 citronella oil Substances 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- FCSHDIVRCWTZOX-DVTGEIKXSA-N clobetasol Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O FCSHDIVRCWTZOX-DVTGEIKXSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
- 229960004134 propofol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229940078465 vanillyl butyl ether Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/066—Multiple emulsions, e.g. water-in-oil-in-water
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
- A23D7/005—Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
- A23D7/0053—Compositions other than spreads
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/80—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/068—Microemulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/925—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of animal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D11/00—Inks
- C09D11/02—Printing inks
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/017—Mixtures of compounds
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K23/00—Use of substances as emulsifying, wetting, dispersing, or foam-producing agents
- C09K23/54—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/26—Optical properties
- A61K2800/262—Transparent; Translucent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本發明提供一種具有可逆的連續及分散相之奈米乳液。該奈米乳液包括水相及油相,該水相與該油相之重量比為1:40至100:1。在該奈米乳液中,該水相以奈米級小液滴形式分散於該油相中或該油相以奈米級小液滴形式分散於該水相中。該水相含有水或水溶液及水溶性有機奈米結構穩定劑。該油相含有油或油溶液、有機凝膠增稠劑及HLB值大於8.0之親水性界面活性劑。亦揭示一種用於製備上述奈米乳液之方法。
Description
存在兩種類型之奈米乳液,亦即,水包油(o/w)奈米乳液及油包水(w/o)奈米乳液。o/w奈米乳液具有連續水相及分散油相,而w/o奈米乳液具有連續油相及分散水相。 此等兩種類型之奈米乳液藉由具有不同親水性親脂性平衡(HLB)值之乳化劑得以穩定。o/w奈米乳液藉由HLB值為8至28之乳化劑得以穩定,且w/o乳液藉由HLB值為3至6之乳化劑得以穩定。因此,其無法輕易地進行相互轉化。 缺乏可易轉化性可能會存在問題。當o/w奈米乳液之含水量降低時,其會發生崩解。同樣,當w/o奈米乳液之含油量降低時,其會發生崩解。 因此,需要研發一種奈米乳液,其連續相及分散相可經該奈米乳液中所包含的同一乳化劑容易進行相互轉化。
本文揭示一種含有可逆的連續及分散相之奈米乳液。 本發明之奈米乳液包括水相及油相,水相與油相之重量比為1:40至100:1。在奈米乳液中,水相以奈米級小液滴形式分散於油相中或油相以奈米級小液滴形式分散於水相中。佔奈米乳液之2.5重量%或大於2.5重量%的水相含有水或水溶液及水溶性有機奈米結構穩定劑。按水相之重量計,水或水溶液之含量小於75%,且按水相之重量計,水溶性有機奈米結構穩定劑之含量小於99%。油相含有油或油溶液、有機凝膠增稠劑及HLB值大於8.0之親水性界面活性劑。按油相之重量計,油或油溶液之含量小於80%,按油相之重量計,有機凝膠增稠劑之含量小於60%,且按油相之重量計,親水性界面活性劑之含量小於60%。此奈米乳液可用作化妝品、食品或醫藥組合物中之活性成分的載體。 用於製備上述奈米乳液之方法亦在本發明之範疇內。該方法包括以下步驟:(1)將水或水溶液與水溶性有機奈米結構穩定劑混合以形成水相,其中按水相之重量計,水或水溶液之含量小於75%,且按水相之重量計,水溶性有機奈米結構穩定劑之含量小於99%;(2)將油或油溶液、有機增稠劑及親水性親脂性平衡值大於8.0之親水性界面活性劑混合以形成油相,其中按油相之重量計,油或油溶液之含量小於80%,按油相之重量計,有機凝膠增稠劑之含量小於60%,且按油相之重量計,親水性界面活性劑之含量小於60%;及(3)將水相與油相混合以形成奈米乳液,水相與油相之重量比為1:40至100:1,其中水或水溶液佔奈米乳液之74重量%或小於74重量%。在適合溫度,例如,5℃至95℃下,進行混合步驟中之每一者。 在由此製得之奈米乳液中,水相以奈米級小液滴形式分散於油相中或油相以奈米級小液滴形式分散於水相中。換言之,奈米乳液中之連續及分散相為可逆的。 一或多個實施例之細節闡述於以下描述中。實施例之其他特徵、目標及優點將由說明書與申請專利範圍變得顯而易見。
本發明係至少部分基於一項意外發現——含有HLB值大於8之親水性界面活性劑的奈米乳液可具有以奈米級小液滴形式分散於油相中之水相或以奈米級小液滴形式分散於水相中之油相。換言之,奈米乳液具有可逆的連續及分散相。 此奈米乳液可帶有油溶性活性成分及水溶性活性成分,其為優於習知奈米乳液之優點。該優點在製備化妝品、食品、家用化學品、農業用產品、印刷產品、染色產品、獸醫用產品、診斷產品、疫苗及醫藥產品方面尤其至關重要,如以下兩個實例所說明。 o/w乳液較佳用於化妝品中,因為相較於w/o乳液,其較不具有黏性及油脂性且具有期望之持水能力。 然而,當將化妝品塗覆至皮膚或暴露於空氣時,化妝品中之奈米乳液會經由蒸發而損失水。水損失會導致習知o/w奈米乳液崩解,而本發明之o/w奈米乳液則不會。取而代之,後一奈米乳液會緩慢轉化成w/o奈米乳液,其中其水相以奈米級小液滴形式均勻地分散於其油相中。 不同地,對於油溶性藥物,較佳使用w/o乳液,歸因於其負載量高。然而,當w/o奈米乳液開始與體液接觸時,由於體液為含水的,其含水量必然會有所增加。因此,習知w/o奈米乳液會發生崩解。而本發明之w/o奈米乳液會緩慢轉化成o/w奈米乳液,其中其油相以奈米級小液滴形式均勻地分散於其水相中。值得注意的是,轉化不僅會維持奈米乳液之完整性且亦會提供其中之藥物的持續釋放。 如上文所指出,本發明之奈米乳液包括水相及油相。在奈米乳液中,水相可以奈米級小液滴形式分散於油相中。或者,油相可以奈米級小液滴形式分散於水相中。 水相包括水溶性有機奈米結構穩定劑。 術語「水溶性有機奈米結構穩定劑」在本文中係指可使奈米乳液之各向同性結構穩定,由此產生熱力學上穩定的透明或半透明奈米乳液的任何水溶性有機成分。其可為水溶性維生素、水溶性肽、水溶性寡肽、多元醇、水溶性醣、水溶性寡醣、雙醣、單醣、氫化碳水化合物、胺基酸、胺基糖或其組合。特定實例包括脲、甲磺醯基甲烷、羥乙基脲、葡糖胺、甘露糖醇、山梨糖醇、木糖醇、乳糖、果糖、右旋糖、核糖、海藻糖、棉子糖、麥芽糖醇、異麥芽糖、乳糖醇、赤藻糖醇、肌醇、牛磺酸、甘油、丙二醇、二丙二醇、丁二醇、己二醇、聚乙二醇、乙氧基乙二醇、肉鹼、精胺酸、吡咯啶酮羧酸鈉及水解膠原蛋白。 油相含有油或油溶液。可使用植物油、聚矽氧油、合成油、礦物油、動物油、精油或其組合來形成油相。特定實例包括椰子油、棕櫚油、葡萄籽油、橄欖油、葡萄柚籽油、亞麻籽油、鱷梨油、月見草油(evening primrose oil)、薰衣草油、迷迭香油、茶樹油、桉油、馬脂、魚油、羊毛脂油、角鯊烯(squalene)、環甲聚矽氧烷、環戊矽氧烷、苯基三甲聚矽氧烷、辛酸/癸酸三甘油酯、十四烷酸異丙酯、異硬脂酸異十八烷基酯、油酸癸酯、異壬酸乙基己酯、異十六烷、辛基十二醇、石蠟油、聚癸烯、聚異丁烯、薄荷醇或其組合。應注意,油溶液含有一或多種作為用於溶解一或多種油溶性溶質之溶劑的油。 亦如上文所指出,油相包括HLB值大於8.0之親水性界面活性劑。較佳地,親水性界面活性劑之HLB值大於10,且更佳地,HLB值大於13。親水性界面活性劑之實例包括聚氧乙烯脫水山梨糖醇脂肪酸酯(Tween 20、Tween 21、Tween 60、Tween 61、Tween 65、Tween 80、Tween 81、Tween 85)、聚氧乙烯山梨糖醇脂肪酸酯、聚氧乙烯酸酯脂肪酸酯(Myri 45、Myri 52、Myri 53、Myri 59)、聚氧乙烯酸脂肪酸酯(Myri 45、Myri 52、Myri 53、Myri 59)、聚氧伸乙基醇酯(Brij 30、Brij 35、Brij 56、Brij 58、Brij 76、Brij 78、Brij 96、Brij 97、Brij 98、Brij 99)、壬基苯酚烷氧基化物(Witconol™基於壬基苯酚之非離子界面活性劑)、烷基烷氧基化物(Ethylan™族非離子界面活性劑)、Pluronic F-127、PEG二甲聚矽氧烷、聚氧乙烯(40)脂肪酸酯、聚氧乙烯(20)醣脂肪酸酯、PEG-15脂肪酸甘油酯、PEG-35氫化蓖麻油、PEG-40氫化蓖麻油、聚甘油脂肪酸酯、脂肪胺衍生物或其組合。 此外,油相含有有機凝膠增稠劑。術語「有機凝膠增稠劑」在本文中係指提高黏度且引起奈米乳液結構性形成之任何物質。有機凝膠增稠劑可為飽和脂肪酸、脂肪酸醇、熔點大於45℃之脂肪酸衍生物或其組合。有機凝膠增稠劑之實例包括硬脂酸、月桂酸、甘油單硬脂酸酯、PEG 6000二硬脂酸酯、單甘油酯、二甘油酯、醣脂肪酸酯、丙二醇脂肪酸酯、二醇脂肪酸酯、脂肪酸己基癸酯、脂肪酸醇、硬脂酸十六烷酯、脂肪抗壞血酸酯、脂肪甘油酯、脂肪己基癸酯或其組合。 在一個實施例中,按水相之重量計,本發明之奈米乳液的水或水溶液之含量小於60%,且按水相之重量計,水溶性有機奈米結構穩定劑之含量小於70%;按油相之重量計,油或油溶液之含量為30%至70%,按油相之重量計,有機凝膠增稠劑之含量小於45%,且按油相之重量計,親水性界面活性劑之含量小於45%;且水或水溶液佔奈米乳液之38重量%或小於38重量%,且水相與油相之重量比為1:3至4:1。較佳地,按水相之重量計,水或水溶液之含量小於45%,且按水相之重量計,水溶性有機奈米結構穩定劑之含量小於50%;按油相之重量計,油或油溶液之含量小於45%至65%,按油相之重量計,有機凝膠增稠劑之含量小於25%,且按油相之重量計,親水性界面活性劑之含量小於35%;且水或水溶液佔奈米乳液之30重量%或小於30重量%,且水相與油相之重量比為1:2至3:1。 本發明之奈米乳液為透明或半透明的,其在3至11之pH下呈固態凝膠形式或液態形式。此外,其展現奈米特徵,亦即,廷得爾光折射效應(Tyndall light refraction effect)。參見Gold and Silver Nanoparticles, Center for Nanoscale Chemical-Electrical-Mechanical Manufacturing Systems, University of Illinois, http:// Nano-cemms.illinois.edu/media/ content/teaching_mats/online/gold_and_silver_nanoparticles/docs/presentation.pdf。 水或水溶液佔奈米乳液之38重量%或小於38重量%之本發明的奈米乳液具有自身防腐能力,且因此不需要在其中包括抗微生物防腐劑。防腐劑通常會引發安全性問題,因為其可能會造成介於輕度頭痛至最嚴重疾病,例如癌症範圍內之健康危害。 當用於化妝品、食品及醫藥組合物中時,此奈米乳液可帶有各種活性成分,例如,特比萘芬(terbinafine)、雙氯芬酸二乙胺、辣椒鹼(capsaicin)、安定(diazepam)、勞拉西泮(lorazepam)、異丙酚、甲硝噠唑、吲哚美辛(indomethacine)、克黴唑、酮康唑、紅黴素、甘寶素、活動素、聯苯苄唑、咪康唑、托萘酯、氯倍他索、益康唑、胺苯甲酸乙酯、苯妥英(phenytoin)、洛伐他汀(lovastatin)、異山梨醇二硝酸酯、***油、法莫替丁(farmotidine)、沒藥醇、葉黃素酯、抑黑素、油溶性維生素、番茄紅素、白藜蘆醇(resveratrol)、人參皂苷(ginsenoiside)、香草基丁基醚、薑黃素及CoQ10。可經由各種途徑,例如,口服、局部、***、經直腸、舌下、肺部及非經腸來投與包括藥物之奈米乳液。若需要,亦可添加某些甜味劑、調味劑、著色劑或芳香劑。 用於製備上述奈米乳液的本發明之方法包括首先分別形成水相及油相,且隨後將兩種相混合。可藉由持續攪拌(手動或以其他方式)、高速及高剪切混合(例如,使用膠體研磨機)、高壓混合(例如,使用微流化劑)或音波處理混合來混合水或水溶液及水溶性有機奈米結構穩定劑以形成水相。油或油溶液、有機增稠劑及親水性界面活性劑亦可由此混合而形成油相。 所得水相及油相可隨後以類似方式混合而形成奈米乳液。值得注意的是,若需要,可在高溫,例如45℃至85℃下進行全部混合步驟。重要的是,由此獲得之油相及水相可用於製備o/w奈米乳液或w/o奈米乳液,其表明連續及分散相為可逆的。 在不進一步詳細描述的情況下,咸信以上描述已充分實現本發明。因此,以下實例應理解為僅為說明性的且無論如何不以任何方式限制本發明之其餘部分。本文中所引用之公開案以全文引用之方式併入本文中。 實例1:奈米乳液類型之測定 將60 ml水置放於100-ml燒杯中。將待測試之奈米乳液逐滴添加至水中。若分散於水中之奈米乳液產生透明或半透明溶液,則所測試之奈米乳液為o/w奈米乳液。然而,若奈米乳液在水中形成油狀小液滴,則所測試之奈米乳液為w/o奈米乳液。 實例2:椰子油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合210公克純化水、90公克脲、60公克木糖醇、60公克海藻糖及30公克甲基磺醯基甲烷之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合80公克椰子油、20公克石蠟油、50公克環甲聚矽氧烷(DC-345)、20公克蜂蠟、10公克單硬脂酸甘油酯、16公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、36公克聚乙二醇脫水山梨糖醇單硬脂酸酯及42公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
在65℃至75℃下藉由在200-ml燒杯中持續手動攪拌來混合下表1中所示之重量比的上文所製備之油相及水相之組合持續低於0.5小時以形成w/o或o/w奈米乳液。 表1
全部奈米乳液在室溫下穩定至少3個月且展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例3:棕櫚油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。 遵照實例2中所述之程序製備由30公克水相及120公克油相組成之150公克w/o奈米乳液,不同之處在於使用棕櫚油代替椰子油。由此製備之奈米乳液為半透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液,不同之處在於使用棕櫚油代替椰子油。由此製備之奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克o/w奈米乳液,不同之處在於使用棕櫚油代替椰子油。由此製備之奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例2中所述之程序製備由75公克水相及25公克油相組成之100公克o/w奈米乳液,不同之處在於使用棕櫚油代替椰子油。由此製備之奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 此實例中所製備之全部奈米乳液均通過遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行的抗微生物測試。 實例4:馬脂奈米乳液之製備 遵照如下所述之程序製備奈米乳液。 遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液,不同之處在於使用馬脂代替椰子油。 遵照實例2中所述之程序製備由60公克水相及40公克油相組成之100公克o/w奈米乳液,不同之處在於使用馬脂代替椰子油。 由此製備之奈米乳液為透明的且在室溫下穩定至少3個月。其均展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的兩種奈米乳液均通過此抗微生物測試。 實例5:馬脂奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克甘露糖醇之組合以形成水相。奈米乳液之油相之製備
遵照實例2中所述之程序製備油相,不同之處在於使用馬脂代替椰子油。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由60公克水相及40公克油相組成之100公克o/w奈米乳液。 由此製備之奈米乳液為透明的且在室溫下穩定至少3個月。其均展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的兩種奈米乳液均通過此抗微生物測試。 實例6:僅含有一種親水性界面活性劑的棕櫚油/角鯊烯奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
藉由在置放於65℃至75℃下之500-ml燒杯中持續手動攪拌來混合180公克純化水、100公克脲、20公克丁二醇之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合100公克棕櫚油、20公克角鯊烯、25公克環甲聚矽氧烷(DC-345)、10公克蜂蠟、20公克硬脂酸、16公克脫水山梨糖醇單硬脂酸酯及60公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合下表2中所示之重量比的上文所製備之油相及水相之組合至多0.5小時以形成亦列於表2中之奈米乳液。 表2
全部以上奈米乳液在室溫下穩定至少3個月且展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例7:基於椰子油之醫藥奈米乳液之製備 遵照如下所述之程序製備奈米乳液。 遵照實例2中所述之程序製備由29.5公克水相、溶解有0.5公克油溶性醫藥活性成分之20公克油相組成之50公克o/w奈米乳液。油溶性醫藥活性成分為特比萘芬、雙氯芬酸二乙胺、二乙胺、甲硝噠唑、吲哚美辛、克黴唑或紅黴素。 由此製備之六種奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例8:基於棕櫚油之醫藥奈米乳液之製備 遵照實例7中所述之程序製備奈米乳液,不同之處在於使用棕櫚油代替椰子油,且油溶性醫藥活性成分為特比萘芬、雙氯芬酸二乙胺、甲康唑(metroconazole)、活動素、聯苯苄唑及咪康唑。 由此製備之六種奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例9:含有甘寶素之精油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克丙二醇之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合40公克茶樹油、20公克桉油、30公克薄荷醇、50公克石蠟油、50公克環甲聚矽氧烷(DC-345)、20公克蜂蠟、10公克單硬脂酸甘油酯、16公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、36公克聚乙二醇脫水山梨糖醇單硬脂酸酯及42公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由90公克水相及60公克油相組成之150公克o/w奈米乳液。 遵照實例2中所述之程序製備由溶解有1公克甘寶素之59公克水相及40公克油相組成之100公克o/w奈米乳液。 全部以上奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例10:具有與實例9中之水相不同之水相的精油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合210公克純化水、90公克脲、60公克木糖醇、60公克海藻糖及30公克甲基磺醯基甲烷之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合40公克茶樹油、20公克桉油、30公克薄荷醇、50公克石蠟油、50公克環甲聚矽氧烷(DC-345)、20公克蜂蠟、10公克單硬脂酸甘油酯、16公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、36公克聚乙二醇脫水山梨糖醇單硬脂酸酯及42公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由90公克水相及60公克油相組成之150公克o/w奈米乳液。 兩種奈米乳液為透明的且在室溫下穩定至少3個月。其均展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing), 第52頁中所述之程序進行抗微生物測試,且此實例中所製備的兩種奈米乳液均通過此抗微生物測試。 實例11:含有托萘酯或酮康唑之精油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克丙二醇之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合50公克茶樹油、20公克桉油、15公克薄荷醇、15公克水楊酸甲酯、50公克環甲聚矽氧烷(DC-345)、10公克蜂蠟、10公克月桂酸、6公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、40公克聚氧乙烯二醇(40)硬脂酸酯及40公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由90公克水相及60公克油相組成之150公克o/w奈米乳液。 遵照實例2中所述之程序製備由60公克水相及溶解有1.8公克托萘酯之88.2公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由60公克水相及溶解有1.8公克酮康唑之88.2公克油相組成之150公克w/o奈米乳液。 全部以上奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例12:芳香劑/精油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克丙二醇之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合80公克檸檬桉油、40公克香茅油、24公克薰衣草油、22公克桉油、15公克迷迭香油、15公克樟腦、15公克薄荷醇、6公克百里香、10公克蜂蠟、10公克月桂酸、6公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、40公克聚氧乙烯二醇(40)硬脂酸酯及40公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由60公克水相及40公克油相組成之100公克o/w奈米乳液。 兩種奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的兩種奈米乳液均通過此抗微生物測試。 實例13:含有CoQ10之中長鏈油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合150公克純化水、100公克甘油、80公克木糖醇、20公克甘露糖醇及30公克甲基磺醯基甲烷之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合170公克中長鏈三酸甘油酯油、16公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、30公克聚乙二醇脫水山梨糖醇單硬脂酸酯及30公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由50公克水相及溶解有5公克CoQ10之95公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由90公克水相及溶解有3公克CoQ10之57公克油相組成之150公克o/w奈米乳液。 遵照實例2中所述之程序製備由120公克水相及溶解有3公克CoQ10之30公克油相組成之153公克o/w奈米乳液。 全部以上奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例14:中長鏈三酸甘油酯奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合100公克純化水、100公克甘油、50公克木糖醇、50公克海藻糖、30公克赤藻糖醇及15公克麥芽糊精之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合170公克中長鏈三酸甘油酯、16公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、30公克聚乙二醇脫水山梨糖醇單硬脂酸酯及30公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由54公克水相及溶解有6公克葉黃素之120公克油相組成之180公克w/o奈米乳液。 遵照實例2中所述之程序製備由174公克水相及溶解有6公克葉黃素之120公克油相組成之300公克o/w奈米乳液。 奈米乳液均為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的兩種奈米乳液均通過此抗微生物測試。 實例15:含有CoQ10之中長鏈三酸甘油酯油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合100公克純化水、100公克甘油、50公克木糖醇、50公克海藻糖、35公克赤藻糖醇及15公克麥芽糊精之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合50公克中長鏈三酸甘油酯、50公克魚油、10公克硬脂酸、8公克脫水山梨糖醇單硬脂酸酯、20公克聚乙二醇脫水山梨糖醇單硬脂酸酯及20公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由20公克水相及溶解有5公克CoQ10之100公克油相組成之125公克w/o奈米乳液。 遵照實例2中所述之程序製備由58公克水相及溶解有2公克CoQ10之40公克油相組成之100公克o/w奈米乳液。 奈米乳液均為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例16:含有異山梨醇二硝酸酯或法莫替丁之角鯊烯/辛酸癸酸三甘油酯奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克丙二醇之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合80公克角鯊烯、80公克辛酸癸酸三甘油酯、16公克硬脂酸、14公克脫水山梨糖醇單硬脂酸酯、40公克聚氧乙烯二醇(40)硬脂酸酯及40公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由90公克水相及60公克油相組成之150公克o/w奈米乳液。 遵照實例2中所述之程序製備由88.5公克水相及溶解有1.5公克異山梨醇二硝酸酯之60公克油相組成之150公克o/w奈米乳液。 遵照實例2中所述之程序製備由88.5公克水相及溶解有1.5公克法莫替丁之60公克油相組成之150公克o/w奈米乳液。 全部以上奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例17:含有薑黃素或睪固酮之合成油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克丙二醇之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合80公克辛酸癸酸三甘油酯、40公克油酸乙酯、40公克脫水山梨糖醇油酸酯、8公克蜂蠟、8公克月桂酸、8公克脫水山梨糖醇單硬脂酸酯及64公克聚氧乙烯二醇(40)硬脂酸酯之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由45公克水相及90公克油相組成之135公克w/o奈米乳液。 遵照實例2中所述之程序製備由45公克水相及溶解有1.8公克睪固酮之88.2公克油相組成之135公克w/o奈米乳液。 遵照實例2中所述之程序製備由45公克水相及溶解有0.6公克薑黃素之89.4公克油相組成之135公克w/o奈米乳液。 全部以上奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的全部奈米乳液均通過此抗微生物測試。 實例18:含有CoQ10、維生素A、維生素E及維生素D之奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合280公克純化水、240公克甘油、48公克脲及32公克海藻糖之組合以形成600公克水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合2.4公克CoQ10、4.8公克維生素A、1.2公克維生素D 1.2、30公克維生素E、85.6公克石蠟油、140公克環甲聚矽氧烷(DC-345)、32公克硬脂酸、24公克脫水山梨糖醇硬脂酸酯及80公克聚乙二醇脫水山梨糖醇單硬脂酸酯之組合以形成400公克油相。奈米乳液之製備
遵照實例2中所述之程序製備由600公克水相及400公克油相組成之1000公克奈米乳液。 以上奈米乳液為透明o/w奈米乳液且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序測定奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且奈米乳液通過此抗微生物測試。 實例19:維生素E/葡萄籽油/椰子油/貂油/石蠟油/環甲聚矽氧烷奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合168公克純化水、115公克脲、77公克甘油、20公克丙二醇、20公克吡咯啶酮羧酸鈉及20公克海藻糖之組合以形成420公克水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合30公克維生素E、30公克葡萄籽油、40公克椰子油、8公克貂油、24公克石蠟油、60公克環甲聚矽氧烷(DC-345)、16公克蜂蠟、8公克單硬脂酸甘油酯、19公克硬脂酸、17公克脫水山梨糖醇單硬脂酸酯、50公克PEG-40氫化蓖麻油及28公克聚氧乙烯二醇(40)硬脂酸酯之組合以形成330公克油相。奈米乳液之製備
遵照實例2中所述之程序製備由420公克水相及330公克油相組成之750公克奈米乳液。 以上奈米乳液為透明o/w奈米乳液且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序測定奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且奈米乳液通過此抗微生物測試。 實例20:維生素E/葡萄籽油/椰子油/貂油/石蠟油/環甲聚矽氧烷奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合168公克純化水、115公克脲、77公克甘油、20公克丙二醇、20公克吡咯啶酮羧酸鈉及20公克海藻糖之組合以形成420公克水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合30公克維生素E、30公克葡萄籽油、40公克椰子油、8公克貂油、24公克石蠟油、60公克環甲聚矽氧烷(DC-345)、16公克蜂蠟、8公克單硬脂酸甘油酯、19公克硬脂酸、17公克脫水山梨糖醇單硬脂酸酯、50公克PEG-40氫化蓖麻油及28公克聚乙二醇脫水山梨糖醇單硬脂酸酯之組合以形成330公克油相。奈米乳液之製備
遵照實例2中所述之程序製備由420公克水相及330公克油相組成之750公克奈米乳液。 以上奈米乳液為透明o/w奈米乳液且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序測定奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且奈米乳液通過此抗微生物測試。 實例21:維生素E/葡萄籽油/椰子油/貂油/石蠟油/環甲聚矽氧烷奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合168公克純化水、115公克脲、77公克甘油、20公克丙二醇、20公克吡咯啶酮羧酸鈉及20公克海藻糖之組合以形成420公克水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合30公克維生素E、30公克葡萄籽油、40公克椰子油、8公克貂油、24公克石蠟油、60公克環甲聚矽氧烷(DC-345)、16公克蜂蠟、8公克單硬脂酸甘油酯、19公克硬脂酸、17公克脫水山梨糖醇單硬脂酸酯、50公克PEG-40氫化蓖麻油及28公克聚氧乙烯脫水山梨糖醇單油酸酯之組合以形成330公克油相。奈米乳液之製備
遵照實例2中所述之程序製備由420公克水相及330公克油相組成之750公克奈米乳液。 以上奈米乳液為透明o/w奈米乳液且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序測定奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且奈米乳液通過此抗微生物測試。 實例22:維生素E/葡萄籽油/椰子油/貂油/石蠟油/環甲聚矽氧烷奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在燒杯中持續手動攪拌來混合150公克純化水、150公克脲及40公克丙二醇之組合以形成340公克水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合30公克維生素E、30公克葡萄籽油、40公克椰子油、8公克貂油、24公克石蠟油、60公克環甲聚矽氧烷(DC-345)、16公克蜂蠟、8公克單硬脂酸甘油酯、19公克硬脂酸、17公克脫水山梨糖醇單硬脂酸酯、50公克PEG-40氫化蓖麻油及28公克聚氧乙烯二醇(40)硬脂酸酯之組合以形成330公克油相。奈米乳液之製備
遵照實例2中所述之程序製備由420公克水相及330公克油相組成之750公克奈米乳液。 以上奈米乳液為透明o/w奈米乳液且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序測定奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且奈米乳液通過此抗微生物測試。 實例23:僅含一種親水性界面活性劑之精油奈米乳液之製備 遵照如下所述之程序製備奈米乳液。奈米乳液之水相之製備
在65℃至75℃下藉由在500-ml燒杯中持續手動攪拌來混合200公克純化水、100公克甘油、50公克葡糖胺及50公克甲基磺醯基甲烷之組合以形成水相。奈米乳液之油相之製備
在65℃至75℃下藉由在400-ml燒杯中持續手動攪拌來混合30公克維生素E、30公克葡萄籽油、40公克椰子油、8公克貂油、24公克石蠟油、60公克環甲聚矽氧烷(DC-345)、16公克蜂蠟、8公克單硬脂酸甘油酯、19公克硬脂酸、17公克脫水山梨糖醇單硬脂酸酯及68公克PEG-40氫化蓖麻油之組合以形成油相。奈米乳液之製備
遵照實例2中所述之程序製備由60公克水相及90公克油相組成之150公克w/o奈米乳液。 遵照實例2中所述之程序製備由90公克水相及60公克油相組成之150公克o/w奈米乳液。 以上奈米乳液為透明的且在室溫下穩定至少3個月。其展現廷得爾光折射效應。 遵照實例1中所述之程序來測定此實例中所製備的各奈米乳液之類型。 遵照USP 35 <51>,抗微生物有效性測試(Antimicrobial Effectiveness Testing),第52頁中所述之程序進行抗微生物測試,且此實例中所製備的兩種奈米乳液均通過此抗微生物測試。其他實施例
本說明書中揭示之所有特徵可以任何組合形式組合。本說明書中揭示之各特徵可經用於相同、等效或類似目的之替代性特徵置換。因此,除非另外明確說明,否則所揭示之各特徵僅為一系列等效或類似通用特徵之一個實例。 根據以上描述,熟習此項技術者可易於確定本發明之基本特徵,且在不脫離本發明之精神及範疇的情況下可對本發明作出各種改變及修改以使其適應各種用途及條件。因此,其他實施例亦處於以下申請專利範圍之範疇內。
無
Claims (23)
- 一種奈米乳液,其包含: (A) 水相,其包括: (1)水或水溶液,及 (2)水溶性有機奈米結構穩定劑, 其中按該水相之重量計,該水或水溶液之含量小於75%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於99%,及 (B) 油相,其包括: (1)油或油溶液, (2)有機凝膠增稠劑,及 (3)親水性親脂性平衡值大於8.0之親水性界面活性劑, 其中按該油相之重量計,該油或油溶液之含量小於80%,按該油相之重量計,該有機凝膠增稠劑之含量小於60%,且按該油相之重量計,該親水性界面活性劑之含量小於60%, 其中該水或水溶液佔該奈米乳液之2.5重量%或大於2.5重量%,該水相與該油相之重量比為1:40至100:1,且該水相以奈米級小液滴形式分散於該油相中或該油相以奈米級小液滴形式分散於該水相中。
- 如請求項1之奈米乳液,其中該油相以該等奈米級小液滴形式分散於該水相中。
- 如請求項1之奈米乳液,其中該水相以該等奈米級小液滴形式分散於該油相中。
- 如請求項2之奈米乳液,其中該親水性親脂性平衡值大於10。
- 如請求項4之奈米乳液,其中該親水性親脂性平衡值大於13。
- 如請求項3之奈米乳液,其中該親水性親脂性平衡值大於10。
- 如請求項6之奈米乳液,其中該親水性親脂性平衡值大於13。
- 如請求項4之奈米乳液,其中該水溶性有機奈米結構穩定劑為水溶性維生素、水溶性肽、水溶性寡肽、多元醇、水溶性醣、水溶性寡醣、雙醣、單醣、氫化碳水化合物、胺基酸、胺基糖或其組合;該油為植物油、聚矽氧油、合成油、礦物油、動物油、精油或其組合;且該有機凝膠增稠劑為飽和脂肪酸、脂肪酸醇、熔點大於45℃之脂肪酸衍生物或其組合。
- 如請求項4之奈米乳液,其中該水溶性有機奈米結構穩定劑為脲、甲磺醯基甲烷、羥乙基脲、葡糖胺、甘露糖醇、山梨糖醇、木糖醇、乳糖、果糖、右旋糖、核糖、海藻糖、棉子糖、麥芽糖醇、異麥芽糖、乳糖醇、赤藻糖醇、肌醇、牛磺酸、甘油、丙二醇、二丙二醇、丁二醇、己二醇、聚乙二醇、乙氧基乙二醇(ethoxydiglycol)、肉鹼、精胺酸、吡咯啶酮羧酸鈉及水解膠原蛋白或其組合;該油為椰子油、棕櫚油、葡萄籽油、葡萄柚籽油、橄欖油、鱷梨油、月見草油(evening primrose oil)、茶樹油、桉油、薰衣草油、迷迭香油、馬脂、魚油、角鯊烯(squalene)、羊毛脂油、環甲聚矽氧烷、環戊矽氧烷、苯基三甲聚矽氧烷、辛酸/癸酸三甘油酯、十四烷酸異丙酯、異硬脂酸異十八烷基酯、油酸癸酯、異壬酸乙基己酯、異十六烷、辛基十二醇、石蠟油、聚異丁烯、聚癸烯、薄荷醇或其組合;該有機凝膠增稠劑為硬脂酸、月桂酸、甘油單硬脂酸酯、PEG 6000二硬脂酸酯、單甘油酯、二甘油酯、醣脂肪酸酯、丙二醇脂肪酸酯、二醇脂肪酸酯、脂肪酸己基癸酯、脂肪酸醇、硬脂酸十六烷酯、脂肪抗壞血酸酯、脂肪甘油酯、脂肪己基癸酯或其組合;且該親水性界面活性劑包括Tween 20、Tween 21、Tween 60、Tween 61、Tween 65、Tween 80、Tween 81、Tween 85、Myri 45、Myri 52、Myri 53、Myri 59、Myri 45、Myri 52、Myri 53、Myri 59、Brij 30、Brij 35、Brij 56、Brij 58、Brij 76、Brij 78、Brij 96、Brij 97、Brij 98、Brij 99、壬基苯酚烷氧基化物、烷基烷氧基化物、Pluronic F-127、PEG二甲聚矽氧烷、聚氧乙烯(40)脂肪酸酯、聚氧乙烯(20)醣脂肪酸酯、PEG-15脂肪酸甘油酯、PEG-35氫化蓖麻油、PEG-40氫化蓖麻油、聚甘油脂肪酸酯、脂肪胺衍生物或其組合。
- 如請求項9之奈米乳液,其中該親水性親脂性平衡值大於13;按該水相之重量計,該水或水溶液之含量小於60%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於50%;按該油相之重量計,該油或油溶液之含量小於45%至65%,按該油相之重量計,該有機凝膠增稠劑之含量小於25%,且按該油相之重量計,該親水性界面活性劑之含量小於35%;該水或水溶液佔該奈米乳液之30重量%或小於30重量%,且該水相與該油相之重量比為1:2至3:1;且該奈米乳液之pH為3至11且為透明或半透明的。
- 如請求項6之奈米乳液,其中該水溶性有機奈米結構穩定劑為水溶性維生素、水溶性肽、水溶性寡肽、多元醇、水溶性醣、水溶性寡醣、雙醣、單醣、氫化碳水化合物、胺基酸、胺基糖或其組合;該油為植物油、聚矽氧油、合成油、礦物油、動物油、精油或其組合;且該有機凝膠增稠劑為飽和脂肪酸、脂肪酸醇、熔點大於45℃之脂肪酸衍生物或其組合。
- 如請求項4之奈米乳液,其中該水溶性有機奈米結構穩定劑為脲、甲磺醯基甲烷、羥乙基脲、葡糖胺、甘露糖醇、山梨糖醇、木糖醇、乳糖、果糖、右旋糖、核糖、海藻糖、棉子糖、麥芽糖醇、異麥芽糖、乳糖醇、赤藻糖醇、肌醇、牛磺酸、甘油、丙二醇、二丙二醇、丁二醇、己二醇、聚乙二醇、乙氧基乙二醇、肉鹼、精胺酸、吡咯啶酮羧酸鈉及水解膠原蛋白或其組合;該油為椰子油、棕櫚油、葡萄籽油、葡萄柚籽油、橄欖油、鱷梨油、月見草油、茶樹油、桉油、薰衣草油、迷迭香油、馬脂、魚油、角鯊烯、羊毛脂油、環甲聚矽氧烷、環戊矽氧烷、苯基三甲聚矽氧烷、辛酸/癸酸三甘油酯、十四烷酸異丙酯、異硬脂酸異十八烷基酯、油酸癸酯、異壬酸乙基己酯、異十六烷、辛基十二醇、石蠟油、聚異丁烯、聚癸烯、薄荷醇或其組合;該有機凝膠增稠劑為硬脂酸、月桂酸、甘油單硬脂酸酯、PEG 6000二硬脂酸酯、單甘油酯、二甘油酯、醣脂肪酸酯、丙二醇脂肪酸酯、二醇脂肪酸酯、脂肪酸己基癸酯、脂肪酸醇、硬脂酸十六烷酯、脂肪抗壞血酸酯、脂肪甘油酯、脂肪己基癸酯或其組合;且該親水性界面活性劑包括Tween 20、Tween 21、Tween 60、Tween 61、Tween 65、Tween 80、Tween 81、Tween 85、Myri 45、Myri 52、Myri 53、Myri 59、Myri 45、Myri 52、Myri 53、Myri 59、Brij 30、Brij 35、Brij 56、Brij 58、Brij 76、Brij 78、Brij 96、Brij 97、Brij 98、Brij 99、壬基苯酚烷氧基化物、烷基烷氧基化物、Pluronic F-127、PEG二甲聚矽氧烷、聚氧乙烯(40)脂肪酸酯、聚氧乙烯(20)醣脂肪酸酯、PEG-15脂肪酸甘油酯、PEG-35氫化蓖麻油、PEG-40氫化蓖麻油、聚甘油脂肪酸酯、脂肪胺衍生物或其組合。
- 如請求項12之奈米乳液,其中該親水性親脂性平衡值大於13;按該水相之重量計,該水或水溶液之含量小於60%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於50%;按該油相之重量計,該油或油溶液之含量小於45%至65%,按該油相之重量計,該有機凝膠增稠劑之含量小於25%,且按該油相之重量計,該親水性界面活性劑之含量小於35%;該水或水溶液佔該奈米乳液之30重量%或小於30重量%,且該水相與該油相之重量比為1:2至3:1;且該奈米乳液之pH為3至11且為透明或半透明的。
- 如請求項8之奈米乳液,其中按該水相之重量計,該水或水溶液之含量小於60%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於70%;按該油相之重量計,該油或油溶液之含量為30%至70%,按該油相之重量計,該有機凝膠增稠劑之含量小於45%,且按該油相之重量計,該親水性界面活性劑之含量小於45%;且該水或水溶液佔該奈米乳液之38重量%或小於38重量%,且該水相與該油相之重量比為1:3至4:1。
- 如請求項14之奈米乳液,其中按該水相之重量計,該水或水溶液之含量小於45%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於50%;按該油相之重量計,該油或油溶液之含量小於45%至65%,按該油相之重量計,該有機凝膠增稠劑之含量小於25%,且按該油相之重量計,該親水性界面活性劑之含量小於35%;且該水或水溶液佔該奈米乳液之30重量%或小於30重量%,且該水相與該油相之重量比為1:2至3:1。
- 如請求項11之奈米乳液,其中按該水相之重量計,該水或水溶液之含量小於60%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於70%;按該油相之重量計,該油或油溶液之含量為30%至70%,按該油相之重量計,該有機凝膠增稠劑之含量小於45%,且按該油相之重量計,該親水性界面活性劑之含量小於45%;且該水或水溶液佔該奈米乳液之38重量%或小於38重量%,且該水相與該油相之重量比為1:3至4:1。
- 如請求項16之奈米乳液,其中按該水相之重量計,該水或水溶液之含量小於45%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於50%;按該油相之重量計,該油或油溶液之含量小於45%至65%,按該油相之重量計,該有機凝膠增稠劑之含量小於25%,且按該油相之重量計,該親水性界面活性劑之含量小於35%;且該水或水溶液佔該奈米乳液之30重量%或小於30重量%,且該水相與該油相之重量比為1:2至3:1。
- 如請求項15之奈米乳液,其中該奈米乳液之pH為3至11且為透明或半透明的。
- 如請求項17之奈米乳液,其中該奈米乳液之pH為3至11且為透明或半透明的。
- 如請求項1之奈米乳液,其中該奈米乳液之pH為3至11且為透明或半透明的。
- 如請求項1之奈米乳液,其中該奈米乳液為自身防腐的。
- 如請求項1之奈米乳液,其中該奈米乳液為化妝品、醫藥產品、食品產品、家用化學品、農業用產品、印刷產品、染色產品、獸醫用產品或診斷產品。
- 一種用於製備奈米乳液之方法,該方法包含: (1)將水或水溶液與水溶性有機奈米結構穩定劑混合以形成水相,其中按該水相之重量計,該水或水溶液之含量小於75%,且按該水相之重量計,該水溶性有機奈米結構穩定劑之含量小於99%; (2)將油或油溶液、有機增稠劑及親水性親脂性平衡值大於8.0之親水性界面活性劑混合以形成油相,其中按該油相之重量計,該油或油溶液之含量小於80%,按該油相之重量計,該有機凝膠增稠劑之含量小於60%,且按該油相之重量計,該親水性界面活性劑之含量小於60%;及 (3)將該水相與該油相混合以形成奈米乳液,該水相與該油相之重量比為1:40至100:1,其中該水或水溶液佔該奈米乳液之74重量%或小於74重量%; 由此該水相以奈米級小液滴形式分散於該油相中或該油相以奈米級小液滴形式分散於該水相中。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/921,572 US9872832B2 (en) | 2015-10-23 | 2015-10-23 | Nanoemulsions having reversible continuous and dispersed phases |
US14/921,572 | 2015-10-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201714605A true TW201714605A (zh) | 2017-05-01 |
TWI769990B TWI769990B (zh) | 2022-07-11 |
Family
ID=57280963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW105134148A TWI769990B (zh) | 2015-10-23 | 2016-10-21 | 具有可逆的連續及分散相之奈米乳液 |
Country Status (15)
Country | Link |
---|---|
US (1) | US9872832B2 (zh) |
EP (1) | EP3159012B1 (zh) |
JP (1) | JP6266051B2 (zh) |
KR (1) | KR101884083B1 (zh) |
CN (1) | CN107028881B (zh) |
AR (1) | AR106403A1 (zh) |
CA (1) | CA2945444C (zh) |
DK (1) | DK3159012T3 (zh) |
ES (1) | ES2753751T3 (zh) |
MX (1) | MX2016013718A (zh) |
MY (1) | MY180028A (zh) |
PH (1) | PH12016000352A1 (zh) |
SG (1) | SG10201608533VA (zh) |
TW (1) | TWI769990B (zh) |
ZA (1) | ZA201606887B (zh) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020502087A (ja) | 2016-12-21 | 2020-01-23 | ユニリーバー・ナームローゼ・ベンノートシヤープ | アミノ酸およびニコチンアミド化合物を含む外用皮膚美白添加物および組成物 |
WO2018114745A1 (en) | 2016-12-21 | 2018-06-28 | Unilever Plc | Personal care compositions comprising poorly soluble compounds |
CN110121330B (zh) | 2016-12-21 | 2022-04-29 | 联合利华知识产权控股有限公司 | 具有包含4-取代的间苯二酚和氨基酸的谷胱甘肽前体的个人护理组合物 |
EA201991185A1 (ru) | 2016-12-21 | 2020-01-13 | Юнилевер Н.В. | Композиции для личной гигиены, содержащие цистин |
US20210000707A1 (en) * | 2017-07-12 | 2021-01-07 | Conopco, Inc., D/B/A Unilever | Nanoemulsions with color stabilized actives |
EP3694476B1 (en) * | 2017-10-10 | 2024-01-31 | Unilever IP Holdings B.V. | Nanoemulsions with neutralized fatty acid and a method producing the same |
US10959975B1 (en) | 2017-11-02 | 2021-03-30 | The Tetra Corporation | Antifungal composition, method of making composition, and method of using composition |
CN107865778A (zh) * | 2017-11-13 | 2018-04-03 | 广州市花安堂生物科技有限公司 | 一种油凝胶组合物及其制备方法和应用 |
WO2019117378A1 (ko) * | 2017-12-15 | 2019-06-20 | 농업회사법인(주)제주우다 | 마유 또는 동백유를 함유하는 나노 에멀젼을 포함하는 화장료 조성물 |
KR102044908B1 (ko) * | 2017-12-27 | 2019-11-14 | 주식회사 메가코스 | 투명성이 개선된 고함량 천연 오일을 함유한 나노 에멀젼 조성물, 이를 포함하는 화장료 조성물 및 이의 제조 방법 |
JP7309720B2 (ja) * | 2018-01-23 | 2023-07-18 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | ラウリン油を含む透明ナノエマルジョンの製造方法 |
JP7266038B2 (ja) * | 2018-01-23 | 2023-04-27 | ユニリーバー・アイピー・ホールディングス・ベスローテン・ヴェンノーツハップ | ラウリン油を含む透明ナノエマルジョン |
KR102067094B1 (ko) * | 2018-04-17 | 2020-01-15 | 김철환 | 비(非)계면활성제형 오일-물(o/w) 분산 조성물, 비(非)계면활성제형 물-오일(w/o) 분산 조성물 및 이들의 제조방법 |
CA3098801C (en) | 2018-05-04 | 2024-04-09 | Johnson & Johnson Consumer Inc. | Cleansing composition comprising stearic esters |
EA202092461A1 (ru) * | 2018-05-23 | 2021-02-20 | Юнилевер Н.В. | Наноэмульсии и способ их получения |
US20220023193A1 (en) * | 2018-11-26 | 2022-01-27 | Colgate-Palmolive Company | Personal Care Compositions |
JP7298863B2 (ja) * | 2018-12-26 | 2023-06-27 | クラシエホームプロダクツ株式会社 | 乳化化粧料 |
US11813354B1 (en) * | 2019-01-11 | 2023-11-14 | Shear Kershman Laboratories, Inc | Trans-mucosal delivery system for testosterone |
US11465107B2 (en) * | 2019-01-31 | 2022-10-11 | Hong Ngoc Thi Dang | Process for producing a nano omega-3 microemulsion system |
CN109691682B (zh) * | 2019-02-22 | 2022-07-01 | 广西中烟工业有限责任公司 | 一种乳化角鲨烯分散液及其制备方法和烟草涂布液 |
CN109662900B (zh) * | 2019-02-25 | 2022-03-22 | 南京华狮新材料有限公司 | 一种磷脂包裹纳米乳组合物及其制备方法和应用 |
CN113557002B (zh) | 2019-04-01 | 2023-11-24 | 联合利华知识产权控股有限公司 | 包含油连续纳米乳液的多重乳液及使用该乳液的方法 |
KR102258968B1 (ko) * | 2019-06-20 | 2021-05-31 | 건국대학교 산학협력단 | 오리 오일을 포함하는 나노에멀젼 및 이의 용도 |
CN112263542B (zh) * | 2020-10-19 | 2023-09-01 | 澳美制药厂有限公司 | ***纳米乳凝胶组合物及其制备方法 |
KR102537101B1 (ko) | 2020-10-28 | 2023-05-30 | 주식회사 메가코스 | 스쿠알렌을 포함하는 나노 에멀젼 조성물, 이를 포함하는 화장료 조성물 및 이의 제조 방법 |
CN112891305B (zh) * | 2021-01-27 | 2022-03-08 | 深圳大学 | 利用不饱和古罗糖醛酸负载白藜芦醇的o/w型纳米乳的制备方法 |
KR102661960B1 (ko) * | 2023-09-07 | 2024-04-29 | 주식회사 뉴앤뉴 | 저 에너지 소요 나노 에멀젼의 제조방법 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06507172A (ja) | 1991-04-19 | 1994-08-11 | アフィニティー バイオテック,インコーポレイテッド | 転換可能なミクロエマルジョン処方剤 |
EP0746331B1 (en) | 1992-10-16 | 2000-09-13 | IBAH, Inc. | Convertible microemulsion formulations |
US6214318B1 (en) * | 1997-10-02 | 2001-04-10 | Oms Holdings Llc | Aerosol ointment compositions for topical use |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US7393548B2 (en) | 1999-03-22 | 2008-07-01 | J.P. M.E.D. Ltd. | Nano oil in glycerin emulsion |
PL354098A1 (en) * | 1999-09-24 | 2003-12-29 | Reckitt Benckiser (Uk) Limitedreckitt Benckiser (Uk) Limited | Skin treatment compositions |
JP2002273192A (ja) * | 2001-03-19 | 2002-09-24 | Yamagata Univ Research Institute | pHにより可逆的に転相する乳化組成物 |
US20080138296A1 (en) * | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
US7488471B2 (en) | 2002-10-28 | 2009-02-10 | Mmp, Inc. | Transparent oil-in-water emulsion |
US20060193813A1 (en) * | 2005-02-11 | 2006-08-31 | L'oreal | Nanoemulsion containing a hydroxylated urea compound |
FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
KR101018819B1 (ko) | 2006-02-14 | 2011-03-04 | (주)아모레퍼시픽 | 티오우레아 유도체를 함유하는 소양성 또는 자극성피부질환의 예방 또는 치료용 외용제 조성물 |
WO2009042166A1 (en) * | 2007-09-25 | 2009-04-02 | Panacos Pharmaceuticals, Inc. | Liquid bevirimat dosage forms for oral administration |
ATE526338T1 (de) * | 2008-04-14 | 2011-10-15 | Cognis Ip Man Gmbh | Alkyl- und/oder alkenylether von alkyl- und/oder alkenyl(poly)glycosiden und ihre verwendung |
CN101664372B (zh) * | 2009-10-12 | 2011-07-06 | 董萍 | 一种皮肤外用抗氧化网络功效纳米乳及其制备方法 |
US20120052126A1 (en) | 2010-08-30 | 2012-03-01 | Yashwant Pathak | Nanoemulsions Containing Antioxidants And Other Health-Promoting Compounds |
CN103690425B (zh) * | 2013-12-12 | 2015-07-22 | 上海应用技术学院 | 一种o/w型含柠檬精油亚微米乳液及其制备方法 |
CN103690379B (zh) * | 2013-12-12 | 2016-02-10 | 上海应用技术学院 | 一种o/w型乳木果油纳米乳液及其制备方法 |
CN104490661A (zh) * | 2014-12-04 | 2015-04-08 | 上海应用技术学院 | 一种含柠檬精油的o/w型纳米乳液及其制备方法 |
-
2015
- 2015-10-23 US US14/921,572 patent/US9872832B2/en active Active
-
2016
- 2016-07-29 JP JP2016150503A patent/JP6266051B2/ja active Active
- 2016-10-04 PH PH12016000352A patent/PH12016000352A1/en unknown
- 2016-10-07 ZA ZA2016/06887A patent/ZA201606887B/en unknown
- 2016-10-12 SG SG10201608533VA patent/SG10201608533VA/en unknown
- 2016-10-17 CA CA2945444A patent/CA2945444C/en active Active
- 2016-10-18 CN CN201610906152.7A patent/CN107028881B/zh active Active
- 2016-10-19 MX MX2016013718A patent/MX2016013718A/es unknown
- 2016-10-19 AR ARP160103185A patent/AR106403A1/es unknown
- 2016-10-20 MY MYPI2016703856A patent/MY180028A/en unknown
- 2016-10-21 TW TW105134148A patent/TWI769990B/zh active
- 2016-10-21 EP EP16195013.4A patent/EP3159012B1/en active Active
- 2016-10-21 KR KR1020160137654A patent/KR101884083B1/ko active IP Right Grant
- 2016-10-21 ES ES16195013T patent/ES2753751T3/es active Active
- 2016-10-21 DK DK16195013T patent/DK3159012T3/da active
Also Published As
Publication number | Publication date |
---|---|
US20170112764A1 (en) | 2017-04-27 |
DK3159012T3 (da) | 2019-11-11 |
AR106403A1 (es) | 2018-01-10 |
MX2016013718A (es) | 2018-04-18 |
CN107028881A (zh) | 2017-08-11 |
BR102016024625A2 (pt) | 2018-03-27 |
CA2945444C (en) | 2022-04-26 |
MY180028A (en) | 2020-11-20 |
KR101884083B1 (ko) | 2018-07-31 |
CN107028881B (zh) | 2021-08-17 |
SG10201608533VA (en) | 2017-05-30 |
KR20170048190A (ko) | 2017-05-08 |
CA2945444A1 (en) | 2017-04-23 |
PH12016000352A1 (en) | 2018-04-11 |
TWI769990B (zh) | 2022-07-11 |
JP2017081896A (ja) | 2017-05-18 |
US9872832B2 (en) | 2018-01-23 |
ZA201606887B (en) | 2017-11-29 |
EP3159012B1 (en) | 2019-08-14 |
JP6266051B2 (ja) | 2018-01-24 |
EP3159012A1 (en) | 2017-04-26 |
ES2753751T3 (es) | 2020-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI769990B (zh) | 具有可逆的連續及分散相之奈米乳液 | |
US20210251948A1 (en) | Nanoemulsion hydrophobic substances | |
JP5946990B2 (ja) | 化粧品及び医薬品使用のための精油を含有する糖系界面活性剤マイクロエマルジョン | |
CA2706517C (en) | Nanoemulsion as delivery vehicles for active components | |
ES2532906T3 (es) | Espuma cosmética y farmacéutica | |
JP2023109849A (ja) | カンナビノイドの希釈可能な製剤及びその調整方法 | |
US9539208B2 (en) | Foam prepared from nanoemulsions and uses | |
ES2393761T3 (es) | Espuma farmacéutica de ácido graso | |
Abolmaali et al. | Pharmaceutical Nanoemulsions and Their Potential Topical and Transdermal Applications: Pharmaceutical nanoemulsions potential applications | |
Chellapa et al. | Nanoemulsion for cosmetic application | |
Kumar et al. | Nanoemulsions: A pharmaceutical review | |
WO2016182926A1 (en) | Preparation of nanoemulsions | |
AU2016247173B2 (en) | Nanoemulsions having reversible continuous and dispersed phases | |
US11504327B1 (en) | Method of preparing nanoparticles by hot-melt extrusion | |
JP2007106674A (ja) | マンゴスチン製剤 | |
JP5706223B2 (ja) | W/o/w型乳化組成物 | |
BR102016024625B1 (pt) | Nanoemulsão e método para preparação da nanoemulsão | |
Ghurghure et al. | A review of nanoemulsion: Formulation approaches and application of nanoemulsion | |
JP2014098014A (ja) | 化粧品及び医薬品使用のための精油を含有する糖系界面活性剤マイクロエマルジョン |